Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) have been given a consensus rating of “Buy” by the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $146.06.

A number of analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $124.00 price target on shares of GW Pharmaceuticals PLC in a research report on Friday, October 6th. ValuEngine cut GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $208.00 target price on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd. Cowen and Company restated an “outperform” rating and set a $165.00 target price on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd. Finally, Leerink Swann restated an “outperform” rating and set a $153.00 target price (down previously from $160.00) on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd.

Institutional investors and hedge funds have recently modified their holdings of the company. Blair William & Co. IL acquired a new position in shares of GW Pharmaceuticals PLC during the first quarter valued at $207,000. Victory Capital Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC by 9.2% during the second quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock valued at $30,971,000 after acquiring an additional 25,920 shares during the period. Eqis Capital Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC by 23.3% during the second quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 547 shares during the period. HighTower Advisors LLC lifted its stake in shares of GW Pharmaceuticals PLC by 10.3% during the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 191 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of GW Pharmaceuticals PLC by 11.0% during the second quarter. Alliancebernstein L.P. now owns 317,956 shares of the biopharmaceutical company’s stock valued at $31,875,000 after acquiring an additional 31,481 shares during the period. 75.07% of the stock is currently owned by institutional investors and hedge funds.

Shares of GW Pharmaceuticals PLC (GWPH) opened at 111.14 on Wednesday. The firm has a 50-day moving average price of $107.77 and a 200-day moving average price of $107.91. The company’s market capitalization is $2.81 billion. GW Pharmaceuticals PLC has a 1-year low of $92.65 and a 1-year high of $136.95.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The company had revenue of $3.14 million during the quarter, compared to the consensus estimate of $2.10 million. During the same quarter last year, the company earned ($0.05) earnings per share. Equities analysts anticipate that GW Pharmaceuticals PLC will post ($6.16) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/10/14/analysts-set-gw-pharmaceuticals-plc-gwph-target-price-at-146-06.html.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.